Cytokinetics announced the endpoints for the clinical trial of tirasemtiv (VITALITY-ALS) had not been met and that further development of the drug was being suspended. We share Cytokinetics, and your, disappointment in this announcement and are grateful for Cytokinetics continued support of the ALS community. Already, Cytokinetics has expressed its commitment to finding new therapies for people with ALS and is hopeful its next treatment, currently in Phase II clinical trials, will be a success. We know the ALS community to be resilient and ever hopeful and we thank you for continuing to join us as we work together to find treatments and a cure for ALS.
Read their full press release, here.
